Effect of pharmaceutical care services on outcomes for home care patients with heart failure

American Journal of Health-System Pharmacy

Volumn 64, Issue 21, 2007, Pages 2244-2249

  Triller, Darren M ^a   Hamilton, Robert A ^b,c  

^a IPRO Inc   (United States)

^b Deparment of Pharmacy   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Clinical pharmacists; Health care; Heart failure; Mortality; Pharmaceutical care; Pharmaceutical services

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOOXYGENASE 2; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; LOOP DIURETIC AGENT; NITRATE; POTASSIUM CHLORIDE; STATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HEART FAILURE; HOME CARE; HOSPITAL READMISSION; HUMAN; INTERVENTION STUDY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL SERVICE; NURSING HOME; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PHARMACIST; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

EID: 36049020976     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050492     Document Type: Article

References (26)

1. Heart disease and stroke statistics - 2005 update. Dallas: American Heart Association; 2005.
2. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316:1429-35.
3. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353:2001-7.
4. Packer M, Bristow MR, Cohn JN et al. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996; 334:1349-55.
5. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336:525-33.
6. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341:709-17.
7. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345:1667-75.
8. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches. J Card Fail. 1999; 5:357-82. [Erratum, J Card Fail. 2000; 6:74.]
9. Kohn LT, Corrigan JM, Donaldson MS. To err is human: building a safer health system. Washington, DC: National Academy Press; 1999.
10. Committee on Quality of Health Care in America. Priority areas for national action: transforming health care quality. http://books.nap.edu/books/ 0309085438/html/42.html#pagetop (accessed 2003 Apr 8).
11. Gurwitz JH, Field TS, Avorn J et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000; 109:87-94.
12. Krska J, Cromarty JA, Arris F et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing. 2001; 30:205-11.
13. Gurwitz JH, Field TS, Harrold LR et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003; 289:1107-16.
14. Gattis WA, Hasselblad V, Whellan DJ et al. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) study. Arch Intern Med. 1999; 159:1939-45.
15. Rainville EC. Impact of pharmacist interventions on hospital readmissions for heart failure. Am J Health-Syst Pharm. 1999; 56:1339-42.
16. Beers MH, Sliwkowski J, Brooks J. Compliance with medication orders among the elderly after hospital discharge. Hosp Formul. 1992; 27:720-4.
17. Gray SL, Mahoney JE, Blough DK. Adverse drug events in elderly patients receiving home health services following hospital discharge. Ann Pharmacother. 1999; 33:1147-53.
18. Gray SL, Mahoney JE, Blough DK. Medication adherence in elderly patients receiving home health services following hospital discharge. Ann Pharmacother. 2001; 35:539-45.
19. Triller DM, Clause SL, Briceland LL et al. Resolution of drug-related problems in home care patients through a pharmacy referral service. Am J Health-Syst Pharm. 2003; 60:905-10.
20. Triller DM, Hamilton RA, Briceland LL et al. Home care pharmacy: extending clinical pharmacy services beyond infusion therapy. Am J Health-Syst Pharm. 2000; 57:1326-31.
21. Stewart S, Vandenbroek AJ, Pearson S et al. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med. 1999; 159:257-61.
22. Rich MW, Beckham V, Wittenberg C et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995; 333:1190-5.
23. Rich MW, Gray DB, Beckham V et al. Effect of a multidisciplinary intervention on medication compliance in elderly patients with congestive heart failure. Am J Med. 1996; 101:270-6.
24. U.S. Census Bureau. State and County QuickFacts. http://quickfacts. census.gov (accessed 2007 Jul 11).
25. Leape LL, Cullen DJ, Clapp MD et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999; 282:267-70.
26. Holland R, Lenaghan E, Harvey I et al. Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial. BMJ. 2005; 330:293.